Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.45 |
| ▸ | PDE1A | P54750 | 3/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262559 | 0.84 | MAPT (0.48) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL4739369 | 0.83 | LMNA (0.52) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL3722773 | 0.82 | LMNA (0.51) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL6188594 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL5262267 | 0.80 | MAPT (0.43) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL8147788 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL25237607 | 0.78 | LMNA (0.52) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL5260494 | 0.77 | CCNB2 (0.45) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL31140713 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNASMN1; SMN2HPGD | |
| SCHEMBL25242471 | 0.75 | ALDH1A1 (0.49) | ALDH1A1MAPTLMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1278749-B1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1278749-A1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6448264-B2 | ANTIPROLIFERATIVE, -CARCINOGENIC AGENTS, ANTIINFLAMMATORY AND -ARTHRITIS AGENTS; NEURODEGENERATIVE DISEASES, E.G., ALZHEIMER'S DISEASE; CARDIOVASCULAR DISORDERS; VIRICIDES; FUNGICIDES | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-20020002178-A1 | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]- pyridines as cyclin dependent kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001081348-A1 | USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO[3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002178-A1 | Use of 5-thio-, sulfinyl- and sulfonylpyrazolo[3,4-b]- pyridines as cyclin dependent kinase inhibitors | CCNI, CDK2, CDK1 | ALDH1A1 1832/4885MAPT 1537/4885LMNA 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.